Cargando…

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

INTRODUCTION: There is limited evidence to guide clinicians on the treatment of psoriasis with biologics in patients with a history of malignancy who are often excluded from clinical trials investigating biologics. The aim of this work is to report a multicenter real-life experience of secukinumab t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellegrini, Cristina, Esposito, Maria, Rossi, Ernesto, Gisondi, Paolo, Piaserico, Stefano, Dapavo, Paolo, Conti, Andrea, Gambardella, Alessio, Burlando, Martina, Narcisi, Alessandra, Offidani, Annamaria, Balestri, Riccardo, Bardazzi, Federico, Prignano, Francesca, Mugheddu, Cristina, Romanelli, Marco, Malara, Giovanna, Schinzari, Giovanni, Fargnoli, Maria Concetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588094/ https://www.ncbi.nlm.nih.gov/pubmed/36169883 http://dx.doi.org/10.1007/s13555-022-00797-9

Ejemplares similares

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
por: TALAMONTI, Marina, et al.
Publicado: (2021)

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
por: COSTANZO, Antonio, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
por: Talamonti, Marina, et al.
Publicado: (2023)

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
por: Gisondi, Paolo, et al.
Publicado: (2021)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
por: Burlando, Martina, et al.
Publicado: (2022)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study
por: Bellinato, Francesco, et al.
Publicado: (2023)

Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
por: Rongioletti, Franco, et al.
Publicado: (2018)

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
por: Scala, Emanuele, et al.
Publicado: (2020)

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
por: Stingeni, Luca, et al.
Publicado: (2023)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective
por: Colombo, Delia, et al.
Publicado: (2022)

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
por: Gisondi, Paolo, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus
por: Damiani, Giovanni, et al.
Publicado: (2023)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
por: Zagni, Emanuela, et al.
Publicado: (2021)

Satisfaction and attitudes toward systemic treatments for psoriasis: A cross‐sectional study
por: Esposito, Maria, et al.
Publicado: (2021)

Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy
por: Argenziano, Giuseppe, et al.
Publicado: (2021)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy
por: Piaserico, Stefano, et al.
Publicado: (2020)

Costo per responder di risankizumab e secukinumab nel trattamento della psoriasi a placche da moderata a grave in Italia
por: Gisondi, Paolo, et al.
Publicado: (2021)

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
por: Bellinato, Francesco, et al.
Publicado: (2022)

Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real‐life multicenter prospective observational cohort study
por: Campanati, Anna, et al.
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing
por: Prignano, Francesca, et al.
Publicado: (2022)

Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus
por: Burlando, Martina, et al.
Publicado: (2022)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Should we be concerned about gastrointestinal‐related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real‐life study
por: Diotallevi, Federico, et al.
Publicado: (2022)

Update on the Management of Pediatric Psoriasis: An Italian Consensus
por: Peris, Ketty, et al.
Publicado: (2022)

Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence
por: Piaserico, Stefano, et al.
Publicado: (2022)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs
por: Gisondi, Paolo, et al.
Publicado: (2021)

MC1R variants predisposing to concomitant primary cutaneous melanoma in a monozygotic twin pair
por: Pellegrini, Cristina, et al.
Publicado: (2012)

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
por: Megna, Matteo, et al.
Publicado: (2022)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1gtj2ph9a7l8f8obn11ep09jjb